About Qantgene
Qantgene is a company based in Berkeley (United States) founded in 2015. Qantgene has raised $12.13 million across 3 funding rounds from investors including Vikor Scientific. Qantgene offers products and services including Qx, Genomic Tumor Profiling, and Qx Plus. Qantgene operates in a competitive market with competitors including GRAIL, Color, Earli, RainDance and NovellusDx, among others.
- Headquarter Berkeley, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Quantgene Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.13 M (USD)
in 3 rounds
-
Latest Funding Round
$6 M (USD), Series B
Feb 18, 2021
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Qantgene
Qantgene offers a comprehensive portfolio of products and services, including Qx, Genomic Tumor Profiling, and Qx Plus.
Platform for early cancer detection using genomics and intelligence.
Service for tumor analysis to improve cancer care outcomes.
Combines genomics with imaging for advanced cancer detection.
People of Qantgene
Unlock access to complete
Funding Insights of Qantgene
Qantgene has successfully raised a total of $12.13M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Qantgene
Qantgene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Vikor Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides rapid molecular diagnostics and testing for pathogens in healthcare settings.
|
Locked | Locked | Locked |
Investor details for Qantgene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Qantgene
Investment portfolio details for Qantgene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Qantgene
Detailed financials for Qantgene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Qantgene Comparisons
Peer comparison for Qantgene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Qantgene
Qantgene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Color, Earli, RainDance and NovellusDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Early cancer detection tests are developed using synthetic biomarkers.
|
|
| Locked | Locked | Locked |
Developer of nucleic acid detection and quantification systems
|
|
| Locked | Locked | Locked |
Developer of technology for precision cancer diagnosis and therapies
|
|
| Locked | Locked | Locked |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
Detailed competitors of Qantgene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Qantgene
Complete news archive for Qantgene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qantgene
Qantgene was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Qantgene is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Qantgene is a funded company, having raised a total of $12.13M across 3 funding rounds to date.
Qantgene was founded in 2015 and is based in Berkeley, United States, within the biotechnology sector. Blood tests for cancer screening and early disease detection are developed and provided. The GRIFFIN Deep Genomics platform is employed, integrating precision sequencing, software, and AI to analyze cell-free DNA fragments. Operations focus on profiling genetic material to support diagnostic applications in healthcare.
Qantgene offers Qx, Genomic Tumor Profiling, and Qx Plus.
Qantgene has 1 investor. Key investors include Vikor Scientific.